Cancer antigen 27-29 (CA27-29) is a protein marker that can be used to detect and monitor the progress of certain types of cancer. It is most commonly associated with breast cancer, but it is also found in other cancers such as ovarian, lung, and gastric cancers. In this blog post, we will discuss the causes, symptoms and treatment for CA27-29 as well as how it is used to diagnose different types of cancer. We will also look at the latest research into this protein marker and explore potential new methods for detecting and monitoring the progression of different types of cancer.
Cancer antigen 27-29 (CA27-29) is a tumor marker for breast cancer. CA27-29 is found in the blood of some women with breast cancer. It may be used to help find breast cancer early. CA27-29 may also be used to see how well treatment is working or to check for breast cancer recurrence.
Cancer is a disease caused by the abnormal growth of cells in the body. Cancerous cells can grow and spread to other parts of the body, which can be life-threatening. The cause of cancer is not fully understood, but it is known that cancerous cells develop when there is a change in the genetic material of a cell. This change can be caused by exposure to certain substances, such as tobacco smoke or radiation. It can also be inherited from a person's parents. There are many different types of cancer, each with its own set of causes.
Cancer antigen (CA) 27-29 is a protein that is found on the surface of some cancer cells. It is used as a marker to help diagnose and monitor certain types of cancer. CA 27-29 levels may be elevated in people with breast, ovarian, or pancreatic cancer.
Elevated CA 27-29 levels may be a sign of cancer, but they can also occur in other conditions.
Additional symptoms that may be associated with CA 27-29 elevation include:
• Fatigue
• Weight loss
• Loss of appetite
• Nausea and vomiting
• Pain
• Jaundice (yellowing of the skin)
Cancer antigen (CA) 27-29 is a protein found on the surface of many types of cancer cells. It is used as a marker to help diagnose certain types of cancer, including ovarian cancer and breast cancer. CA 27-29 levels may also be increased in other conditions, such as benign (non-cancerous) tumors and certain inflammatory diseases.
Cancer antigen 27-29 is a protein that is produced by some types of cancer cells. It is used as a marker to help diagnose and monitor certain types of cancer. Cancer antigen 27-29 levels may be higher in people with:
-Lung cancer
-Breast cancer
-Ovarian cancer
-Colorectal cancer
Cancer antigen 27-29 levels can be measured with a blood test. If the levels are high, it may be an indication that the cancer is present or returning. Treatment for cancer usually involves surgery, chemotherapy, and/or radiation therapy.
Cancer antigen 27-29 is a protein that is produced by some types of cancer cells. This protein can be detected in the blood of people with certain types of cancer, such as ovarian cancer. Cancer antigen 27-29 is not a specific marker for any one type of cancer, but it may be useful in detecting early stage ovarian cancer and other cancers. There is no specific treatment for cancer antigen 27-29, but it is important to detect and treat the underlying cancer as soon as possible.
In conclusion, cancer antigen 27-29 is a protein produced by certain types of cancers and can be used as a marker to diagnose the presence of these diseases. With early diagnosis and proper treatment, cancer caused by CA27-29 may have an improved prognosis. We hope this article has provided you with more information about what CA27-29 is, its causes, symptoms and how it can be treated.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation